Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539122 | 0.84 | FOLH1 (0.33) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL20848346 | 0.83 | ASGR1 (0.38) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL30885813 | 0.81 | ASGR1 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL23225475 | 0.80 | ASGR1 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL6138236 | 0.78 | ASGR1 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL30059357 | 0.78 | CTSS (0.36) | ASGR1 | |
| SCHEMBL18038888 | 0.77 | ASGR1 (0.31) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL17586292 | 0.77 | ASGR1 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL1771222 | 0.75 | FABP4 (0.35) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL23284466 | 0.75 | ASGR1 (0.31) | ASGR1HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115534-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2023-04-13 | — | — | US | disclosed |
| EP-4077283-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127303-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115534-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | GRM1 54/4885ASGR1 1030/4885HDAC1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.